360 results on '"Sachse, Michael"'
Search Results
2. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
3. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
4. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
5. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life
6. Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice
7. 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG
8. Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
9. Quantitative genome-wide association study of six phenotypic subdomains identifies novel genome-wide significant variants in autism spectrum disorder
10. Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases
11. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
12. CLAUDIUS Study: Risk of Materno-Fetal Transmission of Melanoma Cells in Pregnant Women with High Grade Melanoma – A Retrospective Multicenter Study and Literature Review
13. Real‐world outcomes using PD ‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
14. Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases
15. Common functional variants of the glutamatergic system in Autism spectrum disorder with high and low intellectual abilities
16. Kutanes Plattenepithelkarzinom
17. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients
18. Facial emotion recognition in paranoid schizophrenia and autism spectrum disorder
19. Executive and Visuo-Motor Function in Adolescents and Adults with Autism Spectrum Disorder
20. Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
21. Mitarbeiterzufriedenheit als zentrale Leitungsaufgabe
22. The GERMELATOX-A (Dermatologic Cooperative Oncology Group): Study attitude of German melanoma patients towards toxicity during adjuvant treatment.
23. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
24. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
25. Follicular red dots of the hip in frontal fibrosing alopecia – do we have to look twice?
26. Follikuläre Rötungen an der Hüfte bei frontal fibrosierender Alopezie–Müssen wir genauer schauen?
27. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
28. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG
29. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
30. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
31. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders
32. Group-based cognitive behavioural psychotherapy for children and adolescents with ASD: the randomized, multicentre, controlled SOSTA – net trial
33. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
34. Plattenepithelkarzinom der Haut
35. Current diagnosis and treatment of basal cell carcinoma
36. Aktuelle Diagnostik und Behandlung des Basalzellkarzinoms
37. The heat shrink tube technology – a simple method for making hair cross sections
38. Die Schrumpfschlauchtechnik – Eine einfache Methode zur Herstellung von Haarschaftquerschnitten
39. Primary human hepatocytes are protected against complement by multiple regulators
40. Rezidivrisiko minimieren
41. PET/CT bei Patienten mit Melanom: eine Zweiklassenversorgung? Stand der Versorgung mit PET/CT in der primären Ausbreitungsdiagnostik des Melanoms
42. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
43. ADHD and autism: differential diagnosis or overlapping traits? A selective review
44. Synaptic, transcriptional and chromatin genes disrupted in autism
45. Rückbildung B-RAF-Inhibitor-assoziierter Keratoakanthome durch Acitretin - welche Auswirkungen haben Retinoide auf den RAF/MEK/ERK-Signalweg?: Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
46. Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
47. Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
48. PET/CT in malignant melanoma: a two‐tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT
49. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
50. Cutaneous and systemic plasmocytosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.